Back to Oncology
Oncologyv2018Evidence-Based

2018 Leibovich Model for Renal Cell Carcinoma (RCC)

Predicts progression-free and cancer-specific survival in patients with renal cell carcinoma (RCC) using clinical, surgical, and pathologic factors

Clinical Input Parameters

years
Range: 18 — 100 years
cm
Range: 0.5 — 25 cm
Clinical Assessment
Awaiting Parameters
leibovich score
—points
Ready to Calculate

Awaiting Clinical Input

Enter the clinical input parameters on the left and click Run Clinical Assessment to evaluate this medical calculator with deterministic clinical scoring.

Open in Web App
Clinical decision support tool for licensed medical practitioners. Confirm independently before prescribing or clinical action.

When & Why to Use

The 2018 Leibovich Model for Renal Cell Carcinoma (RCC) is utilized in clinical practice for risk stratification, diagnostic probability estimation, and treatment decision-making within oncology.

Use this tool during initial patient intake, emergency department workup, or bedside assessment when objective clinical scoring is required to guide management or admission decisions.

Clinical Formula & Scoring Logic

Scoring based on clinical, surgical, and pathologic factors with separate models for progression-free survival (PFS) and cancer-specific survival (CSS)

Clinical Pearls & Practice Notes

  • This model applies specifically to clear cell renal cell carcinoma (ccRCC)
  • Separate scoring algorithms exist for progression-free survival and cancer-specific survival
  • The model was developed for non-metastatic RCC patients
  • Age scoring: <60 years = 0 points, ≥60 years = 1 point (CSS only)
  • Tumor size scoring varies by outcome (PFS vs CSS) and specific size ranges
  • Constitutional symptoms include fever, night sweats, and weight loss
  • ECOG 0 = fully active, ≥1 = restricted in activity

Evidence & Literature Citations

  1. Thompson RH, Leibovich BC, Cheville JC, et al. Negative impact of sarcomatoid differentiation on the outcome of clear cell renal cell carcinoma. Am J Surg Pathol. 2018;42(4):474-481.
  2. Leibovich BC, Blute ML, Cheville JC, et al. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer. 2003;97(7):1663-71.
  3. Thompson RH, Cheville JC, Lohse CM, et al. Reclassification of patients with pT3 and pT4 renal cell carcinoma improves prognostic accuracy. Cancer. 2005;104(1):53-60.

Score Interpretation Ranges

Low Risk0 – 4 pts

Excellent prognosis

Intermediate Risk5 – 9 pts

Good prognosis

High Risk10 – 14 pts

Poor prognosis

Very High Risk15 – 20 pts

Very poor prognosis

Need Clinical Suite Access?

Run this calculator with patient history, laboratory integration, and drug interaction safety checks on the DexaMed clinician app.

Open in Web App

Clinical Decision Support (CDS) Notice & Legal Disclaimer

This medical calculator and its scoring interpretation are provided strictly for licensed healthcare professionals and medical trainees as an educational and clinical decision support instrument. It does not replace independent clinical judgment, comprehensive patient history, physical examination, or attending physician oversight. Not FDA-cleared as an autonomous diagnostic medical device. Read the full DexaMed Medical Disclaimer.